Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients | VBI Vaccines

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

February 8, 2021 | Publications

View More

March 2, 2021

VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021

March 1, 2021

VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference

February 2, 2021

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine

January 21, 2021

VBI Vaccines Announces Progress of Coronavirus Vaccine Program

January 15, 2021

VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

December 23, 2020

VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine

December 7, 2020

VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

December 2, 2020

VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI